Valuation : Revance Therapeutics, Inc.

Market Cap 319M 274M 257M 236M 440M 30.15B 443M 3.05B 1.19B 15.41B 1.2B 1.17B 49.62B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 468M 439M 401M 749M 51.37B 755M 5.19B 2.02B 26.25B 2.04B 2B 84.55B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
18.21
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-79.90% 383M
-0.83%+4.72%+50.03%+2.79% 85.08B
-4.44%+0.91%+499.06%+31.74% 60.21B
+0.95%+1.77%-15.77%-34.78% 59.71B
-1.60%-7.63%-3.65%+31.05% 51.1B
+0.09%-0.54%+9.26%+170.07% 48.73B
+0.58%+1.23%+58.33%-15.79% 32.9B
-0.24%+0.72%+47.95%+103.32% 26.11B
+0.79%-6.56%-2.56%+192.31% 22.6B
+1.10%-1.67%+64.17%+113.16% 16.42B
Average -0.32%-1.26%+70.68%+51.40% 40.33B
Weighted average by Cap. -0.76%-0.78%+93.72%+45.38%

Financials

2022 2023
Net sales 133M 114M 107M 97.93M 183M 12.53B 184M 1.27B 493M 6.4B 498M 487M 20.63B 234M 201M 189M 173M 323M 22.12B 325M 2.24B 871M 11.31B 879M 860M 36.41B
Net income -356M -307M -288M -263M -491M -33.69B -495M -3.4B -1.33B -17.22B -1.34B -1.31B -55.45B -324M -279M -262M -239M -447M -30.63B -450M -3.09B -1.21B -15.65B -1.22B -1.19B -50.41B
Net Debt 77.76M 66.91M 62.79M 57.44M 107M 7.35B 108M 743M 289M 3.76B 292M 286M 12.1B 225M 193M 181M 166M 310M 21.22B 312M 2.14B 835M 10.85B 843M 825M 34.93B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock